Drugs / PC13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05396300 | May 2022 → Jun 2026 | colorectal cancer, gastric cancer | Weijia Fang, MD | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PC13 | “evaluated the safety and efficacy of PC13, a hypoxia-responsive, carcinoembryonic antigen (CEA)-targeted CAR T cell therapy” PMID 41760800 ↗ Feb 2026 |
| Modality | Cell therapy | “a hypoxia-responsive, carcinoembryonic antigen (CEA)-targeted CAR T cell therapy” PMID 41760800 ↗ Feb 2026 |